Immuno-Oncology Program

About Bessor Pharma

Bessor Pharma is a privately held, pre-revenue biotech company leveraging a dual-strategy of therapeutic and platform development. Its core focus is on advancing novel small molecule programs in immuno-oncology and inflammation, while simultaneously building a proprietary biomimetic chemical synthesis platform to access a new class of natural product-like compounds. The company's model involves de-risking projects internally before seeking partnerships, supported by a leadership team with deep industry experience in drug development, chemistry, and business strategy.

About Tiba Biotech

Founded in 2020 and based in Cambridge, Massachusetts, Tiba Biotech is a private, preclinical biotech emerging from a 5-year sponsored research program at M.I.T. and the Whitehead Institute. The company is developing a proprietary RNA platform that integrates a novel, biodegradable delivery nanoparticle with advanced computational RNA design, aiming to create safer and more potent vaccines and therapeutics. With a seasoned leadership team and backing from global foundations and government partners like NIH, BARDA, and CEPI, Tiba is initially targeting influenza vaccines while building a pipeline in oncology and genetic medicines.

Therapeutic Areas